The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | LOTIS-9: Loncastuximab tesirine and rituximab in unfit/frail patients with DLBCL
Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly shares some insights into the LOTIS-9 trial (NCT05144009), which is evaluating the efficacy and tolerability of loncastuximab tesirine (Lonca-T) plus rituximab in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are unfit for standard chemotherapy. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Kite/Gilead, BMS, Novartis, Genentech/Roche, Morphosys/Incyte, AstraZeneca, Janssen, Calithera, and ADC Therapeutics, and consulting with Kite/Gilead, BMS, Novartis, Genentech/Roche, Morphosys/Incyte, AstraZeneca, Janssen, Calithera, ADC Therapeutics, Merck, and MonteRosa.
